Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Update

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the target of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 235,208 shares, a drop of 16.4% from the January 29th total of 281,277 shares. Approximately 4.8% of the company’s shares are short sold. Based on an average trading volume of 38,252 shares, the short-interest ratio is currently 6.1 days. Based on an average trading volume of 38,252 shares, the short-interest ratio is currently 6.1 days. Approximately 4.8% of the company’s shares are short sold.

Sunshine Biopharma Trading Down 3.3%

Shares of SBFM opened at $1.16 on Tuesday. Sunshine Biopharma has a 1-year low of $1.13 and a 1-year high of $3.90. The firm’s 50-day moving average price is $1.23 and its 200-day moving average price is $1.44. The firm has a market capitalization of $5.70 million, a price-to-earnings ratio of -1.14 and a beta of 1.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SBFM. Citadel Advisors LLC lifted its stake in shares of Sunshine Biopharma by 23.1% in the 3rd quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock valued at $116,000 after purchasing an additional 14,656 shares during the period. Virtu Financial LLC purchased a new stake in Sunshine Biopharma in the fourth quarter worth $29,000. Finally, Two Sigma Investments LP purchased a new stake in Sunshine Biopharma in the third quarter worth $32,000. Hedge funds and other institutional investors own 41.98% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sunshine Biopharma in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $7.00.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.